Skip to main content

drug discovery Archives

nference and Vanderbilt University Medical Center sign agreement to advance real-world evidence generation in complex disease populations

Jul. 25, 2023—nference, a science-first software company transforming healthcare by making biomedical data computable, and Vanderbilt University Medical Center have announced a strategic agreement aimed at advancing research through the deployment of nference's state-of-the-art federated clinical analytics platform. By leveraging the power of federated AI and machine learning, this collaboration will expand clinical insights in key research areas.

Read more


A speedier treatment for depression?

Jul. 11, 2022—Vanderbilt researchers used a computer-based search to identify a compound with promise as a new, mechanistically distinct and rapid-acting therapy for major depressive disorder.

Read more


Looking beyond the ‘magic bullet’ approach to drug discovery

May. 1, 2018—Vanderbilt scientists have developed a new process that can rapidly and inexpensively identify personalized cancer drugs derived from nature.

Read more


Nashville Biosciences created to leverage wealth of data

Apr. 5, 2018—Officials with Vanderbilt University Medical Center announced the creation of a wholly owned subsidiary, Nashville Biosciences, to harness the power of its extensive genomic and bioinformatics resources to advance drug and diagnostics discovery and development.

Read more


Boehringer Ingelheim and Vanderbilt University expand partnership to develop novel treatment approaches for cancer

Mar. 14, 2018—New agreement will pursue therapies targeting MCL1 (myeloid cell leukemia 1), which is highly prevalent in many difficult-to-treat cancers.

Read more


Vanderbilt signs licensing, research agreements to develop new approach to schizophrenia treatment

Jan. 8, 2018—Under the terms of the licensing agreement, Lundbeck has exclusively licensed rights to compounds developed at Vanderbilt that act on a receptor in the brain that has been implicated in schizophrenia.

Read more


Goal of new tissue-chip research is to assess efficacy of novel epilepsy drugs

Sep. 20, 2017—An interdisciplinary team of Vanderbilt University researchers has received a two-year, $2-million federal grant to develop an “organ-on-chip” model for two genetic forms of epilepsy.

Read more


Vanderbilt, Bayer collaborate to develop new therapies against kidney diseases

Sep. 11, 2017—Vanderbilt University Medical Center (VUMC) and Bayer have agreed on a five-year strategic research alliance to evaluate new drug candidates for the treatment of kidney diseases, with the goal of accelerating the translation of innovative approaches from the laboratory to pre-clinical development.

Read more


Vanderbilt begins Phase 1 trials of new Alzheimer’s drug

Aug. 7, 2017—Developed at Vanderbilt, VU319 is designed to precisely target a specific neuron receptor associated with cognitive function while avoiding potentially dangerous side effects.

Read more


Vanderbilt, Ono Pharmaceutical extend drug discovery agreement

May. 25, 2017—Vanderbilt University Medical Center (VUMC), Vanderbilt University and Japan-based Ono Pharmaceutical Co. Ltd. have expanded a drug discovery agreement initiated in 2015 that will now run through 2019.

Read more


Fighting fungal infections

Apr. 3, 2017—A detailed structural and functional analysis of the yeast protein that is the main target of antifungal drugs will help direct efforts to develop better treatments.

Read more


Investigational new drug for Alzheimer’s scheduled for first study in humans

Dec. 27, 2016—Vanderbilt University scientists have received notification from the U.S. Food and Drug Administration that testing in humans may proceed for an investigational new drug for Alzheimer's disease after more than 10 years of research by scientists at Vanderbilt University and Vanderbilt University Medical Center.

Read more


Recent Stories from VUMC News and Communications Publications

Vanderbilt Medicine
Hope
Momentum
VUMC Voice

more